KALA BIO faces possible Nasdaq delisting over $1 rule
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
KALA BIO, Inc. (KALA) disclosed that on August 27, 2026 it received a Staff Determination Letter from Nasdaq stating that its common stock has failed to meet the $1.00 minimum closing bid price requirement for The Nasdaq Capital Market for 30 consecutive business days from July 16 through August 26, 2026. Under normal circumstances, this would trigger a 180-day grace period, but Nasdaq determined KALA is not eligible for any compliance period because it effected a 1-for-50 reverse stock split on May 11, 2026 within the prior year. KALA plans to timely request a hearing before the Nasdaq Hearings Panel, which will stay any suspension or delisting action while the Panel considers the matter. The company states there is no assurance that continued listing will be granted or that it will regain and maintain compliance with the Minimum Bid Price Requirement or other Nasdaq listing standards.
Positive
- None.
Negative
- Nasdaq delisting risk with no automatic cure period: KALA BIO’s stock traded below $1.00 for 30 consecutive business days, and because it completed a 1-for-50 reverse stock split on May 11, 2026, Nasdaq did not grant the usual 180-day compliance period, increasing near-term listing uncertainty.
8-K Event Classification
Key Figures
Key Terms
Minimum Bid Price Requirement market
Nasdaq Listing Rule 5550(a)(2) regulatory
Nasdaq Listing Rule 5810(c)(3)(A)(iv) regulatory
reverse stock split financial
Nasdaq Hearings Panel regulatory
forward-looking statements regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Nasdaq notice did KALA (KALA) receive about its listing?
Why didn’t KALA (KALA) get a 180-day grace period from Nasdaq?
What minimum bid price requirement is KALA (KALA) currently not meeting?
How does KALA (KALA) plan to respond to Nasdaq’s determination?
Is there any assurance KALA (KALA) will remain listed on Nasdaq?
AI-generated analysis. How Rhea-AI works. Not financial advice.